ISG to Evaluate Life Sciences Digital Services
MWN-AI** Summary
Information Services Group (ISG), a leading global technology research and advisory firm, is set to release a comprehensive report titled "Life Sciences Digital Services" in April 2026. This report will critically analyze IT service providers and contract research organizations (CROs) across vital operational dimensions in the life sciences sector. The study aims to highlight how these providers facilitate AI-driven digital transformation throughout the life sciences value chain.
With the rising cost of innovation, life sciences enterprises are increasingly seeking strategic partnerships with CROs to enhance their data integration and modernize outdated systems. Key service areas examined in the report will include digital clinical development, patient engagement, manufacturing and supply chain logistics, pharmacovigilance, regulatory affairs, and commercial operations.
ISG will survey over 80 providers, collaborating with its advisors to categorize the digital services into eight distinct quadrants, focusing on Clinical Development, Patient Engagement, Manufacturing and Supply Chain, and Commercial Operations, among others. These categorization efforts will provide invaluable insights for enterprise buyers looking to evaluate their vendor relationships, identify potential new engagements, and explore available services.
Significant trends driving this digital shift include platform consolidation, patient-centered designs, and hybrid trial models. Moreover, clearer regulations surrounding decentralized trials and remote monitoring are accelerating the adoption of advanced technologies within the sector. As enterprises move towards enterprise-grade digital transformation, the application of cutting-edge tools like Generative AI is becoming increasingly important.
The forthcoming report not only serves as a resource for enterprises but also aids ISG advisors in validating market insights and guiding their clients in selecting suitable providers. For more information, interested parties can visit the ISG Provider Lens webpage.
MWN-AI** Analysis
The upcoming ISG Provider Lens report on Life Sciences Digital Services is poised to serve as a crucial resource for enterprises in the life sciences sector, particularly as they navigate the complexities of digital transformation. Enterprises are increasingly reliant on strategic partnerships, including contract research organizations (CROs) and IT service providers, to modernize their operations and integrate advanced technological solutions.
As the report highlights, organizations are prioritizing scalable digital strategies that leverage cloud data platforms, AI-driven tools, and interoperable systems. The emphasis on Good x Practice (GxP) compliance is critical for sustaining trust and effectiveness in digital clinical development and pharmacovigilance. Consequently, businesses should assess their current vendor relationships and potential new partners based on their ability to facilitate this digital evolution.
Investors should pay close attention to providers that excel in the eight defined quadrants: from enhancing clinical development processes with data-driven methodologies to improving patient engagement through omnichannel platforms and digital therapeutics. The report also evaluates manufacturers who embrace process automation and robust supply chain solutions, all essential components for building resilient operations.
Moreover, continued advancements in regulatory affairs, particularly with AI-enabled tools for case processing and signal detection, will shape compliance strategies, presenting opportunities for strategic stakeholders. The robust focus on patient-centric designs, hybrid trial models, and innovative digital solutions further signals a transformative stage in life sciences.
In summary, enterprises should leverage insights from the ISG Provider Lens report to identify leading providers that can drive their digital strategies effectively. Engaging with firms that demonstrate a strong commitment to innovation and compliance will be vital for success in this evolving landscape, making the report a key tool for informed decision-making.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Upcoming ISG Provider Lens ® report will examine how providers enable digital, AI-driven transformation across the life sciences value chain
Information Services Group ( ISG ) (Nasdaq: III ), a global AI-centered technology research and advisory firm, has launched a research study examining IT service providers and contract research organizations (CROs) across key digital and operational areas in the life sciences domain.
The study results will be published in a comprehensive ISG Provider Lens ® report, called Life Sciences Digital Services, scheduled to be released in April 2026. The report will cover companies offering services such as digital clinical development, patient engagement, manufacturing and supply chain, pharmacovigilance and regulatory affairs and commercial operations, including the capabilities of CROs.
Enterprise buyers will be able to use information from the report to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm’s buy-side clients.
Life sciences enterprises are turning to strategic providers, including CROs, to unify fragmented data and modernize legacy systems. As innovation costs rise, organizations are prioritizing scalable digital strategies built on cloud data platforms, Good x Practice (GxP)-compliant AI and interoperable systems to strengthen core operations. Factors such as platform consolidation, patient-centric design and hybrid trial models are accelerating digital adoption among enterprises in this domain, supported by clearer regulations for decentralized trials and remote monitoring.
“Enterprises are moving decisively from experimentation to true, enterprise-grade digital transformation,” said Iain Fisher, director at ISG. “They are rapidly adopting advanced technologies such as GenAI copilots to support critical life sciences processes including protocol design, labeling and safety reporting.”
ISG has distributed surveys to more than 80 providers. Working in collaboration with ISG’s global advisors, the research team will produce eight quadrants representing the digital services that the typical life sciences enterprise is buying, based on ISG’s experience working with its clients. The eight quadrants are:
- Clinical Development (Service Providers) , evaluating providers’ capabilities in facilitating efficient, compliant and data-driven drug development. They are further examined on their ability to accelerate trial timelines, improve data integrity and enable decentralized and hybrid trial models.
- Patient Engagement (Service Providers) , assessing providers delivering omnichannel platforms, mobile health tools and digital therapeutics that enhance patient education, adherence and retention. Providers in this space should combine life sciences expertise with robust digital platforms.
- Manufacturing and Supply Chain (Service Providers), covering providers that can facilitate digitally connected, compliant and resilient operations across drug and device manufacturing. They should demonstrate expertise in process automation, predictive maintenance and quality control.
- Pharmacovigilance and Regulatory Affairs — Digital Evolution (Service Providers), evaluating providers offering AI-enabled case processing, signal detection and regulatory intelligence solutions. They are assessed on their ability to comply with varied life sciences regulatory standards and their proficiency in workflow automation.
- Commercial Operations — Digital Evolution (Service Providers), evaluating providers’ potential and strategic vision in commercial operations. Providers should focus on how their technology enables data-driven, omnichannel engagement and commercial excellence for life sciences organizations.
- Clinical Development (CROs), examining CROs delivering digitally enabled, decentralized and hybrid clinical trial services. CROs should combine scientific depth with digital innovation to provide patient-centric clinical research outcomes.
- Patient Engagement (CROs), covering CROs providing digital and behavioral science-based engagement tools that improve patient recruitment, onboarding and retention. Key evaluation areas include mobile applications, wearables and AI-driven analytics that enable personalized, real-time interaction with patients.
- Pharmacovigilance and Regulatory Affairs — Digital Evolution (CROs), assessing CROs’ ability and effectiveness in managing drug safety, compliance and global submissions. They need to demonstrate success in reducing case turnaround times and enhancing submission accuracy.
Geographically focused reports from the study will cover the global life sciences digital services market and examine products and services available worldwide. ISG analysts Rohan Sinha and Sneha Jayanth will serve as authors of the report.
A list of identified providers and vendors and further details on the study are available in this digital brochure . Companies not listed as digital service providers in the life sciences domain can contact ISG and ask to be included in the study.
All 2025 ISG Provider Lens ® evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG’s continuous CX research.
About ISG Provider Lens ® Research
The ISG Provider Lens ® Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage .
About ISG
ISG (Nasdaq: III ) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251208138954/en/
Press Contacts:
Laura Hupprich, ISG
+1 203-517-3100
laura.hupprich@isg-one.com
Julianna Sheridan, Matter Communications for ISG
+1 978-518-4520
isg@matternow.com
FAQ**
How is Information Services Group Inc. III planning to leverage its AI-centered research to enhance the digital and operational capabilities of life sciences providers in the upcoming ISG Provider Lens report?
What specific criteria will Information Services Group Inc. III use to evaluate the effectiveness of contract research organizations (CROs) in facilitating digital transformation across the life sciences value chain?
In what ways does Information Services Group Inc. III's upcoming research intend to address the challenges enterprises face in modernizing legacy systems within the life sciences sector?
How will the findings from Information Services Group Inc. III's report on Life Sciences Digital Services impact enterprise buyers' decisions regarding vendor relationships in the evolving landscape of digital health solutions?
**MWN-AI FAQ is based on asking OpenAI questions about Information Services Group Inc. (NASDAQ: III).
NASDAQ: III
III Trading
-2.28% G/L:
$4.192 Last:
28,624 Volume:
$4.17 Open:
